<DOC>
	<DOCNO>NCT00528372</DOCNO>
	<brief_summary>The purpose clinical research study determine whether dapagliflozin improve ( decrease ) blood glucose value patient Type 2 diabetes never treat medication take medication le 24 week since original diabetes diagnosis . The safety treatment also study .</brief_summary>
	<brief_title>A Phase III Study BMS-512148 ( Dapagliflozin ) Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet Exercise</brief_title>
	<detailed_description>All eligible participant receive single-blind placebo medication 2-week lead-in period . All participant may receive additional open-label treatment metformin , 500-2000 mg , need rescue , base protocol specific criterion .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Key Inclusion Criteria Males female , age 18 77 year Type 2 diabetes inadequate glycemic control , define : Group 1 , hemoglobin A1c ( HbA1c ) ≥7 % ≤10 % ; Group 2 , HbA1c ≥10.1 % ≤12.0 % Drug naive , define never receive prescription medication diabetes , receive prescription medication diabetes &lt; 24 week since original diagnosis Cpeptide ≥1.0 ng/mL enrollment Body Mass Index ≤ 45.0 kg/m^2 enrollment Key Exclusion Criteria Urine albumin : creatinine ratio &gt; 1,800 mg/g Aspartate aminotransferase &gt; 3*upper limit normal ( ULN ) Alanine aminotransferase &gt; 3*ULN Serum total bilirubin &gt; 2*ULN Serum creatinine ≥1.5 mg/dL men ; ≥1.4 mg/dLfor woman Calcium value outside central laboratory normal reference range Positive hepatitis B surface antigen Positive antihepatitis C virus antibody Hemoglobin ≤11 g/dL men ; hemoglobin ≤10 g/dL woman Creatine kinase &gt; 3*ULN Abnormal free T4 value History diabetes insipidus Symptoms poorly control diabetes , include mark polyuria polydipsia great 10 % weight loss 3 month prior enrollment History diabetic ketoacidosis hyperosmolar nonketotic coma Severe uncontrolled hypertension define systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg Any follow within 6 month enrollment : Myocardial infarction , cardiac surgery revascularization , unstable angina , unstable congestive heart failure ( CHF ) , CHF New York Heart Association Class III IV status , transient ischemic attack significant cerebrovascular disease , unstable previously undiagnosed arrhythmia History unstable rapidly progress renal disease Conditions congenital renal glucosuria Significant hepatic disease , include chronic active hepatitis and/or severe hepatic insufficiency Documented history hepatotoxicity medication Documented history severe hepatobiliary disease History hemoglobinopathy , exception sickle cell trait , thalassemia minor , chronic recurrent hemolysis Donation blood blood product blood bank , blood transfusion , participation clinical study require withdrawal &gt; 400 mL blood 6 week prior enrollment Malignancy ( exception treat basal cell treat squamous cell carcinoma ) within 5 year enrollment visit Known immunocompromised status , include individual undergone organ transplantation positive HIV result Administration antidiabetic therapy 14 day ( consecutive ) 12 week prior enrollment Administration antidiabetic therapy , previously specify , dose , time 4 week prior enrollment Replacement chronic systemic corticosteroid therapy , define dose systemic corticosteroid take &gt; 4 week within 3 month prior enrollment History bariatric surgery lapband procedure Administration sibutramine , phentermine , orlistat , rimonabant , benzphetamine , diethylpropion , methamphetamine , and/or phendimetrazine , within 30 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>